SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus
NEW YORK, January 2, 2026, 05:03 ET — Premarket SELLAS Life Sciences Group (SLS) shares rose about 10% in U.S. premarket trading on Friday to $4.14, after gaining 13.9% in the prior regular session. Early trading ranged between $4.13 and $4.32. Public+1 The move matters because SELLAS’ valuation hinges on a single late-stage cancer study, and timing signals can drive sharp swings in small-cap biotech stocks. Investors have been trading around when the company will reach its next, predefined trial milestone — a threshold that determines when researchers can run the final analysis. On Dec. 29, SELLAS said its contract